NRD
BMY icon

Nebula Research & Development’s Bristol-Myers Squibb BMY Stock Holding History

Nebula Research & Development’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,742
Closed -$405K – 127
2025
Q2 		$405K Buy
+8,742
New +$429K 0.03% 699
2025
Q1 		– Sell
-12,527
Closed -$709K – 963
2024
Q4 		$709K Buy
+12,527
New +$700K 0.08% 422
2023
Q4 		– Sell
-8,973
Closed -$521K – 655
2023
Q3 		$521K Buy
+8,973
New +$550K 0.27% 120

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nebula Research & Development's BMY Position: Q3 2025 in Review

Nebula Research & Development sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 8,742 shares — an estimated $405K sold.

Nebula Research & Development first reported a position in BMY in Q3 2023 and held it in 3 quarters. The position peaked at $709K in Q4 2024. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

  • Nebula Research & Development reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 8,742 Bristol-Myers Squibb shares in Q3 2025, an estimated $405K.
  • Nebula Research & Development first reported a position in Bristol-Myers Squibb in Q3 2023 and held it in 3 quarters.
  • Nebula Research & Development's Bristol-Myers Squibb position peaked at $709K in Q4 2024.
  • 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.